EIC Transition for the development of a novel precision gene therapy for brain tumors
Reference number | |
Coordinator | Sox Therapeutics AB |
Funding from Vinnova | SEK 298 972 |
Project duration | June 2025 - September 2025 |
Status | Ongoing |
Venture | Global cooperation 2025 |
Call | Planning grant for international proposal 2025 |
Purpose and goal
Sox Therapeutics AB is developing SOX01, a novel precision gene therapy for brain tumors. This treatment targets cancer cells that are resistant to standard therapies. We have demonstrated early success for recurrent brain tumors. We are seeking EIC funding to advance toward clinical trials. This planning project aims to strengthen Sox Therapeutics´s competitiveness in the upcoming EIC Transition application.
Expected effects and result
The project will result in Sox Therapeutics being fully prepared to submit a competitive application to the EIC Transition. Expected results include a comprehensive project plan, timeline, and budget, a validated technical concept with feasibility assessments for key components; legal and regulatory analysis; a socioeconomic impact study; and a preliminary business strategy. All these elements will become parts of a strong EIC Transition application.
Planned approach and implementation
The project will be organized into 4 work packages: 1. Preparation of Project Plan and Work Packages for EIC Transition Application Start: (25/06/2025 - 16/07/2025), 2. Vector optimization and regulatory strategy development (25/06/2025 - 22/09/2025), 3. Development of a socioeconomic impact, business and IP strategy (25/06/2025 - 05/09/2025), 4. Strong EIC Transition Application (07/07/2025 - 22/09/2025) The work will be carried out by the Sox team supported by consultants.